Compare · RVMD vs TSBX
RVMD vs TSBX
Side-by-side comparison of Revolution Medicines Inc. (RVMD) and Turnstone Biologics Corp. (TSBX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVMD and TSBX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD carries a market cap of $45.31B.
- RVMD has hit the wire 13 times in the past 4 weeks while TSBX has been quiet.
- RVMD has more recent analyst coverage (25 ratings vs 6 for TSBX).
- Company
- Revolution Medicines Inc.
- Turnstone Biologics Corp.
- Price
- $214.32+1.47%
- $0.36+1.63%
- Market cap
- $45.31B
- -
- 1M return
- +16.16%
- -
- 1Y return
- +472.34%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2023
- News (4w)
- 13
- 0
- Recent ratings
- 25
- 6
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest RVMD
- Revolution Medicines Inc. filed SEC Form 8-K: Other Events
- U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
- General Counsel Cislini Jeff exercised 56,280 shares at a strike of $20.00 and sold $11,904,247 worth of shares (56,894 units at $209.24) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 55,907 units (SEC Form 4)
- Officer Goldsmith Mark A exercised 80,000 shares at a strike of $4.73 and sold $17,991,107 worth of shares (86,000 units at $209.20) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- SEC Form SCHEDULE 13G filed by Revolution Medicines Inc.
- BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
Latest TSBX
- SEC Form 15-12G filed by Turnstone Biologics Corp.
- SEC Form 4 filed by Director Orbimed Advisors Llc
- Amendment: SEC Form SCHEDULE 13D/A filed by Turnstone Biologics Corp.
- SEC Form 4 filed by Large owner Versant Ventures V, Llc
- SEC Form S-8 POS filed by Turnstone Biologics Corp.
- SEC Form S-8 POS filed by Turnstone Biologics Corp.
- Turnstone Biologics Corp. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant
- Amendment: SEC Form SC 14D9/A filed by Turnstone Biologics Corp.
- SEC Form 25-NSE filed by Turnstone Biologics Corp.
- Amendment: SEC Form SC TO-T/A filed by Turnstone Biologics Corp.